Botulinum toxin prevents radiotherapy-induced salivary gland damage

Teymoortash, Afshin; Muller, F.; Juricko, Janko; Bieker, Michael; Mandic, Robert; Librizzi, Damiano; Höffken, H.; Pfestroff, Andeas; Werner, Jochen A.

doi:10.1016/j.oraloncology.2008.11.014

Cited by 37 publications

(24 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several studies have reported the successful use of BTX in the management of hypersalivation in specific neurologic and otolaryngologic disorders (24, 25). Furthermore, the injection of BTX into rat SMGs has been recently shown to attenuate radiation-induced glandular atrophy and periductal fibrosis (26). Therefore, we speculated that BTX pretreatment induces a dormant salivary state, which in turn could protect from radiation damage.…”

Section: Discussionmentioning

confidence: 99%

Botulinum Toxin Confers Radioprotection in Murine Salivary Glands

Zeidan

Xiao

Cao

et al. 2016

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

Purpose Xerostomia is a common radiation sequela, which has a negative impact on the quality of life of patients with head and neck cancer. Current treatment strategies offer only partial relief. Botulinum toxins (BTX) have been successfully used in treating a variety of radiation sequelae such as cystitis, proctitis, fibrosis, and facial pain. The purpose of this study was to evaluate the effect of BTX on radiation-induced salivary gland damage. Methods and Materials We used a previously established model for murine salivary gland irradiation (IR). The submandibular glands (SMGs) of C5BL/6 mice (n=6/group) were injected with saline or BTX 72 hours before receiving 15 Gy of focal irradiation. Saliva flow was measured 3, 7, and 28 days after treatment. The SMGs were collected for immunohistochemistry, confocal microscopy, and Western blotting. A cytokine array consisting of 40 different mouse cytokines was used to evaluate cytokine profiles after radiation treatment. Results Irradiated mice showed a 50% reduction in saliva flow after 3 days, whereas mice preinjected with BTX had 25% reduction in saliva flow (P<.05). Cell death detected by TUNEL staining was similar in SMG sections of both groups. However, neutrophil infiltrate, detected by myeloperoxidase staining, was 3-fold lower for the BTX treated mice. A cytokine array showed a 2-fold upregulation of LPS-induced chemokine (LIX/CXCL5) 3 days after IR. BTX pretreatment reduced LIX levels by 40%. At 4 weeks after IR, the saline (control) group showed a 40% reduction in basal SMG weight, compared with 20% in the BTX group. Histologically, BTX-pretreated glands showed relative preservation of acinar structures after radiation. Conclusions These data suggest that BTX pretreatment ameliorates radiation-induced saliva dysfunction. Moreover, we demonstrate a novel role for CXCL5 in the acute phase of salivary gland damage after radiation. These results carry important clinical implications for the treatment of xerostomia in patients with head and neck cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Botulinum Toxin Confers Radioprotection in Murine Salivary Glands

Zeidan

Xiao

Cao

et al. 2016

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

show abstract

“…Teymoortash et al 158 suggested the utilization of botulinum toxin as an alternative preventive against salivary damage caused by ionizing radiation. The intraglandular application of the toxin, prior to radiotherapy, significantly prevented functional and histological changes in rats.…”

Section: Preventive Therapiesmentioning

confidence: 99%

Salivary hypofunction: An update on aetiology, diagnosis and therapeutics

Saleh

Figueiredo

Cherubini

et al. 2015

Archives of Oral Biology

198

166

View full text Add to dashboard Cite

“…A preclinical rat model has recently demonstrated that intraglandular injection of BoNT before RT reduces glandular injury. 66 The mechanism of action of this treatment is unclear and two hypotheses have been proposed: (1) a temporary glandular involution leading to reduction of saliva production during RT, avoiding concentration of radiation where inorganic solutes from saliva are located or (2) an action on the nitric oxide pathway. Furthermore, BoNT has been shown to increase tumor response to RT in an experimental model, suggesting that this treatment would not have the risk of tumor protection.…”

Section: Protection Of the Salivary Glands During Rtmentioning

confidence: 99%

Cost-effectiveness landscape analysis of treatments addressing xerostomia in patients receiving head and neck radiation therapy

Sasportas

Hosford

Sodini

et al. 2013

Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology

View full text Add to dashboard Cite

Head and neck (H&N) radiation therapy (RT) can induce irreversible damage to the salivary glands thereby causing long-term xerostomia or dry mouth in 68%–85% of the patients. Not only does xerostomia significantly impair patients’ quality-of-life (QOL) but it also has important medical sequelae, incurring high medical and dental costs. In this article, we review various measures to assess xerostomia and evaluate current and emerging solutions to address this condition in H&N cancer patients. These solutions typically seek to accomplish 1 of the 4 objectives: (1) to protect the salivary glands during RT, (2) to stimulate the remaining gland function, (3) to treat the symptoms of xerostomia, or (4) to regenerate the salivary glands. For each treatment, we assess its mechanisms of action, efficacy, safety, clinical utilization, and cost. We conclude that intensity-modulated radiation therapy is both the most widely used prevention approach and the most cost-effective existing solution and we highlight novel and promising techniques on the cost-effectiveness landscape.

show abstract

Botulinum toxin prevents radiotherapy-induced salivary gland damage

Cited by 37 publications

References 10 publications

Botulinum Toxin Confers Radioprotection in Murine Salivary Glands

Botulinum Toxin Confers Radioprotection in Murine Salivary Glands

Salivary hypofunction: An update on aetiology, diagnosis and therapeutics

Cost-effectiveness landscape analysis of treatments addressing xerostomia in patients receiving head and neck radiation therapy

Contact Info

Product

Resources

About